<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>FENOGLIDE- fenofibrate tablet </strong><br>Santarus, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use FENOGLIDE® safely and effectively. See full prescribing information for FENOGLIDE. <br>FENOGLIDE (fenofibrate) Tablets, for oral use<br>Initial U.S. Approval: 1993
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">FENOGLIDE is a peroxisome proliferator receptor alpha (PPARα) activator indicated as an adjunct to diet:
 </p>
<ul class="Disc">
<li>to reduce elevated LDL-C, Total-C, TG, and <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span>, and to increase HDL-C in adult patients with primary <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span> or mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span>. (<a href="#s2">1.1</a>)
</li>
<li>to treat adult patients with severe <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>. (<a href="#s3">1.2</a>)
</li>
</ul>
<p class="Highlighta">Important Limitation of Use: Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus. (<a href="#s14">5.1</a>)
 </p>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<ul class="Disc">
<li>Primary <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span> or mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span>: 120 mg per day (<a href="#s7">2.2</a>)
</li>
<li>Severe <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>: 40 to 120 mg per day; the dose should be adjusted according to patient response (<a href="#s8">2.3</a>)
</li>
<li>Renally impaired patients: Initial dose of 40 mg per day; the dose should be increased according to the effect on renal function and lipid levels (<a href="#s9">2.4</a>)
</li>
<li>Geriatric patients: Select dose on the basis of renal function (<a href="#s10">2.5</a>)
</li>
</ul>
<p class="Highlighta">To increase absorption of FENOGLIDE, take with food.
 </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disc"><li>Oral tablets: 40 mg and 120 mg 
</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li>Severe renal dysfunction, including patients receiving dialysis (<a href="#s12">4</a>, <a href="#s37">8.6</a>, <a href="#s43">12.3</a>)
</li>
<li>Active liver disease (<a href="#s12">4</a>, <a href="#s16">5.3</a>)
</li>
<li><span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">Gallbladder disease</span> (<a href="#s12">4</a>, <a href="#s18">5.5</a>)
</li>
<li>Nursing mothers (<a href="#s12">4</a>, <a href="#s34">8.3</a>)
</li>
<li>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to fenofibrate (<a href="#s12">4</a>)
</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span> and <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> have been reported in patients taking fenofibrate. The risk for serious muscle toxicity is increased when fibrates are co-administered with a statin (with a significantly higher rate observed for gemfibrozil), particularly in elderly patients and in patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, or <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>. (<a href="#s15">5.2</a>)
</li>
<li>Fenofibrate can increase serum transaminases. Monitor liver tests, including ALT, periodically during therapy. (<a href="#s16">5.3</a>)
</li>
<li>Fenofibrate can reversibly increase serum creatinine levels. (<a href="#s17">5.4</a>) Monitor renal function periodically in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. (<a href="#s37">8.6</a>)
</li>
<li>Fenofibrate increases <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> excretion into the bile, leading to risk of <span class="product-label-link" type="condition" conceptid="4098112" conceptname="Biliary sludge">cholelithiasis</span>. If <span class="product-label-link" type="condition" conceptid="4098112" conceptname="Biliary sludge">cholelithiasis</span> is suspected, gallbladder studies are indicated. (<a href="#s18">5.5</a>)
</li>
<li>Exercise caution in concomitant treatment with coumarin anticoagulants. Adjust the dosage of coumarin to maintain the <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time/INR at the desired level to prevent <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> complications. (<a href="#s19">5.6</a>)
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions (&gt; 2% and at least 1% greater than placebo) are abnormal liver tests, increased AST, increased ALT, increased CPK, and <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>. (<a href="#s24">6</a>)
 </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact</span> Santarus Inc. at 1-888-778-0887 <span class="Bold">or FDA at 1-800-FDA-1088 or
</span><span class="Bold Italics">www.fda.gov/medwatch</span>.
 </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc">
<li>Coumarin Anticoagulants: (<a href="#s28">7.1</a>)
</li>
<li>Immunosupressants: (<a href="#s29">7.2</a>)
</li>
<li>Bile-Acid Binding Resins: (<a href="#s30">7.3</a>)
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc">
<li>Geriatric Use: Determine dose selection on the basis of renal function. (<a href="#s36">8.5</a>)
</li>
<li><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span>: Avoid use in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Dose reduction is required in patients with mild to moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. (<a href="#s37">8.6</a>)
</li>
</ul></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div>
<div></div>
<div></div>
</div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 8/2012</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE
</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Primary <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">Hypercholesterolemia</span> and Mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span>
</a></h2>
<h2><a href="#section-1.2" class="toc">1.2 Severe <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span>
</a></h2>
<h2><a href="#section-1.3" class="toc">1.3 Important Limitations of Use
</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION
</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 General Considerations
</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Primary <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">Hypercholesterolemia</span> or Mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span>
</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Severe <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span>
</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span>
</a></h2>
<h2><a href="#section-2.5" class="toc">2.5 Geriatric Patients
</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS
</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS
</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS
</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Mortality and Coronary Heart Disease Morbidity
</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Skeletal Muscle
</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Liver Function
</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Serum Creatinine
</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="4098112" conceptname="Biliary sludge">Cholelithiasis</span>
</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Coumarin Anticoagulants
</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span>
</a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Hematologic Changes
</a></h2>
<h2><a href="#section-5.9" class="toc">5.9 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span>
</a></h2>
<h2><a href="#section-5.10" class="toc">5.10 Venothromboembolic Disease
</a></h2>
<h2><a href="#section-5.11" class="toc">5.11 Paradoxical Decreases in HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> Levels
</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS
</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience
</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience
</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS
</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Coumarin Anticoagulants
</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Immunosuppressants
</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Bile-Acid Binding Resins
</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Colchicine
</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS
</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy
</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers
</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use
</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use
</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>
</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE
</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION
</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY
</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action
</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics
</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics
</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY
</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES
</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Primary <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">Hypercholesterolemia</span> (Heterozygous Familial and Nonfamilial) and Mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span>
</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Severe <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span>
</a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING
</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION
</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s2"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Primary <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">Hypercholesterolemia</span> and Mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span>
</h2>
<p class="First">FENOGLIDE is indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (LDL-C), total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (Total-C), Triglycerides (TG), and <span class="product-label-link" type="condition" conceptid="4122128" conceptname="Apolipoprotein">apolipoprotein</span> B (<span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span>), and to increase high-density lipoprotein (HDL-C) in adult patients with primary <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span> or mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s3"></a><a name="section-1.2"></a><p></p>
<h2>1.2 Severe <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span>
</h2>
<p class="First">FENOGLIDE is also indicated as adjunctive therapy to diet for treatment of adult patients with severe <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>. Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia thereby obviating the need for pharmacologic intervention.
</p>
<p>Markedly elevated levels of serum triglycerides (e.g. &gt;2,000 mg/dL) may increase the risk of developing <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>. The effect of FENOGLIDE therapy on reducing this risk has not been adequately studied.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s4"></a><a name="section-1.3"></a><p></p>
<h2>1.3 Important Limitations of Use
</h2>
<p class="First">Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus [<span class="Italics">see Warnings and Precautions (<a href="#s14">5.1</a>)</span>].
</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s5"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s6"></a><a name="section-2.1"></a><p></p>
<h2>2.1 General Considerations
</h2>
<p class="First">FENOGLIDE tablets should be given with food to optimize the absorption of the medicine. Patients should be advised to swallow FENOGLIDE Tablets whole. Do not crush, dissolve or chew tablets.
</p>
<p>The initial treatment for <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span> is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcoholic intake may be important factors in <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span> and should be addressed prior to any drug therapy. Physical exercise can be an important ancillary measure. Diseases contributory to <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>, such as <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span> or <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus should be looked for and adequately treated. Estrogen therapy, thiazide diuretics and beta-blockers, are sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>. In such cases, discontinuation of the specific etiologic agent may obviate the need for specific drug therapy of <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>.
</p>
<p>Lipid levels should be monitored periodically and consideration should be given to reducing the dosage of FENOGLIDE if lipid levels <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> significantly below the targeted range.
</p>
<p>Therapy should be withdrawn in patients who do not have an adequate response after two months of treatment with the maximum recommended dose of 120 mg once daily.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s7"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Primary <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">Hypercholesterolemia</span> or Mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span>
</h2>
<p class="First">The initial dose of FENOGLIDE is 120 mg per day.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s8"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Severe <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span>
</h2>
<p class="First">The initial dose is 40 to 120 mg per day. Dosage should be individualized according to patient response, and should be adjusted if necessary following repeat lipid determinations at 4 to 8 week intervals. The maximum dose is 120 mg per day.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s9"></a><a name="section-2.4"></a><p></p>
<h2>2.4 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span>
</h2>
<p class="First">Treatment with FENOGLIDE should be initiated at a dose of 40 mg per day in patients with mild to moderately <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>, and increased only after evaluation of the effects on renal function and lipid levels at this dose. The use of FENOGLIDE should be avoided in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> [<span class="Italics">see Use in Specific Populations (<a href="#s37">8.6</a>) and Clinical Pharmacology (<a href="#s43">12.3</a>)</span>].
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s10"></a><a name="section-2.5"></a><p></p>
<h2>2.5 Geriatric Patients
</h2>
<p class="First">Dose selection for the elderly should be made on the basis of renal function [<span class="Italics">see Use in Specific Populations (<a href="#s36">8.5</a>)</span>].
</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="s11"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS
</h1>
<ul class="Disc">
<li>40 mg: White to off-white oval tablets. Debossed "FLO".
</li>
<li>120 mg: White to off-white oval tablets. Debossed "FHI".
</li>
</ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s12"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS
</h1>
<p class="First">FENOGLIDE is contraindicated in:
</p>
<ul class="Disc">
<li>patients with severe renal dysfunction, including those receiving dialysis [<span class="Italics">see Clinical Pharmacology (<a href="#s43">12.3</a>)</span>]
</li>
<li>patients with active liver disease, including those with <span class="product-label-link" type="condition" conceptid="4135822" conceptname="Primary biliary cirrhosis">primary biliary cirrhosis</span> and unexplained persistent liver function abnormalities [<span class="Italics">see Warnings and Precautions (<a href="#s16">5.3</a>)</span>].
</li>
<li>in patients with pre-existing <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span> [<span class="Italics">see Warnings and Precautions (<a href="#s18">5.5</a>)</span>].
</li>
<li>nursing mothers [<span class="Italics">see Use in Specific Populations (<a href="#s34">8.3</a>)</span>].
</li>
<li>patients with a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to fenofibrate [see Warnings and Precautions (<a href="#s22">5.9</a>)].
</li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="s13"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s14"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Mortality and Coronary Heart Disease Morbidity
</h2>
<p class="First">The effect of FENOGLIDE on coronary heart disease morbidity and mortality and non-cardiovascular mortality has not been established.
</p>
<p>The Action to Control Cardiovascular Risk in <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Lipid (ACCORD Lipid) trial was a randomized placebo-controlled study of 5518 patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus on background statin therapy treated with fenofibrate. The mean duration of follow-up was 4.7 years. Fenofibrate plus statin combination therapy showed a non-significant 8% relative risk reduction in the primary outcome of major adverse cardiovascular events (MACE), a composite of non-fatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, non-fatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, and cardiovascular disease <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> (hazard ratio [HR] 0.92, 95% CI 0.79-1.08) (p=0.32) as compared to statin monotherapy. In a gender subgroup analysis, the hazard ratio for MACE in men receiving combination therapy versus statin monotherapy was 0.82 (95% CI 0.69-0.99), and the hazard ratio for MACE in women receiving combination therapy versus statin monotherapy was 1.38 (95% CI 0.98-1.94) (interaction p=0.01). The clinical significance of this subgroup finding is unclear.
</p>
<p>The Fenofibrate Intervention and Event Lowering in <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> (FIELD) study was a 5-year randomized, placebo-controlled study of 9,795 patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus treated with fenofibrate. Fenofibrate demonstrated a non-significant 11% relative reduction in the primary outcome of coronary heart disease events (hazard ratio [HR] 0.89, 95% CI 0.75-1.05, p=0.16) and a significant 11% reduction in the secondary outcome of total cardiovascular disease events (HR 0.89 [0.80-0.99], p=0.04). There was a non-significant 11% (HR 1.11 [0.95, 1.29], p=0.18) and 19% (HR 1.19 [0.90, 1.57], p=0.22) increase in total and coronary heart disease mortality, respectively, with fenofibrate as compared to placebo.
</p>
<p>Because of chemical, pharmacological, and clinical similarities between fenofibrate, clofibrate, and gemfibrozil, the adverse findings in 4 large randomized, placebo-controlled clinical studies with these other fibrate drugs may also apply to FENOGLIDE.
</p>
<p>In the Coronary Drug Project, a large study of post <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> of patients treated for 5 years with clofibrate, there was no difference in mortality seen between the clofibrate group and the placebo group. There was however, a difference in the rate of <span class="product-label-link" type="condition" conceptid="4098112" conceptname="Biliary sludge">cholelithiasis</span> and <span class="product-label-link" type="condition" conceptid="192956" conceptname="Cholecystitis">cholecystitis</span> requiring surgery between the two groups (3.0% vs. 1.8%).
</p>
<p>In a study conducted by the World Health Organization (WHO), 5000 subjects without known <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> were treated with placebo or clofibrate for 5 years and followed for an additional one year. There was a statistically significant, higher age-adjusted all-cause mortality in the clofibrate group compared with the placebo group (5.70% vs. 3.96%, p=&lt;0.01). Excess mortality was due to a 33% increase in non-cardiovascular causes, including malignancy, post-cholecystectomy complications, and <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>. This appeared to confirm the higher risk of <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span> seen in clofibrate-treated patients studied in the Coronary Drug Project.
</p>
<p>The Helsinki Heart Study was a large (n=4,081) study of middle-aged men without a history of <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>. Subjects received either placebo or gemfibrozil for 5 years, with a 3.5 year open extension afterward. Total mortality was numerically higher in the gemfibrozil randomization group but did not achieve statistical significance (p=0.19, 95% confidence interval for relative risk G:P=0.91-1.64). Although cancer <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> trended higher in the gemfibrozil group (p=0.11), cancers (excluding basal cell carcinoma) were diagnosed with equal frequency in both study groups. Due to the limited size of the study, the relative risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> from any cause was not shown to be different than that seen in the 9 year follow-up data from the WHO study (RR=1.29).
</p>
<p>A secondary prevention component of the Helsinki Heart Study enrolled middle-aged men excluded from the primary prevention study because of known or suspected coronary heart disease. Subjects received gemfibrozil or placebo for 5 years. Although cardiac <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> trended higher in the gemfibrozil group, this was not statistically significant (hazard ratio 2.2, 95% confidence interval: 0.94-5.05).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s15"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Skeletal Muscle
</h2>
<p class="First">Fibrates increase the risk for <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> and have been associated with <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>. The risk for serious muscle toxicity appears to be increased in elderly patients and in patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, or <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>.
</p>
<p><span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span> should be considered in any patient with diffuse <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgias</span>, muscle <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, and/or marked elevations of creatine phosphokinase (CPK) levels.
</p>
<p>Patients should be advised to report promptly unexplained <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, particularly if accompanied by <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span> or <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. CPK levels should be assessed in patients reporting these symptoms, and FENOGLIDE therapy should be discontinued if markedly elevated CPK levels occur or <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>/<span class="product-label-link" type="condition" conceptid="73001" conceptname="Myositis">myositis</span> is suspected or diagnosed.
</p>
<p>Data from observational studies indicate that the risk for <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> is increased when fibrates, in particular gemfibrozil, are co-administered with an HMG-CoA reductase inhibitor (statin). The combination should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk of this drug combination <span class="Italics">[see Clinical Pharmacology (<a href="#s43">12.3</a>)].</span></p>
<p>Cases of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, have been reported with fenofibrates co-administered with colchicine, and caution should be exercised when prescribing fenofibrate with colchicine. [<span class="Italics">see Drug Interactions (<a href="#e30">7.4</a>)</span>]
								</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s16"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Liver Function
</h2>
<p class="First">Fenofibrate at doses equivalent to 87 mg to 130 mg fenofibrate per day [at the highest dose, comparable to FENOGLIDE, 120 mg] has been associated with increases in serum transaminases [AST (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>) or ALT (SGPT)].
</p>
<p>In a pooled analysis of 10 placebo-controlled trials, increases to &gt;3 times the upper limit of normal occurred in 5.3% of patients taking fenofibrate versus 1.1% of patients treated with placebo. When transaminase determinations were followed either after discontinuation of treatment or during continued treatment, a return to normal limits was usually observed. The incidence of increases in transaminases related to fenofibrate therapy appears to be dose related. In an 8-week dose-ranging study, the incidence of ALT or AST elevations to at least three times the upper limit of normal was 13% in patients receiving dosages equivalent to 87 mg to 130 mg fenofibrate per day and was 0% in those receiving dosages equivalent to 43 mg or less fenofibrate per day, or placebo.
</p>
<p>Hepatocellular, chronic active and <span class="product-label-link" type="condition" conceptid="4318541" conceptname="Cholestatic hepatitis">cholestatic hepatitis</span> have been reported after exposures of weeks to several years. In extremely rare cases, cirrhosis has been reported in association with <span class="product-label-link" type="condition" conceptid="4026125" conceptname="Chronic active hepatitis">chronic active hepatitis</span>.
</p>
<p>Baseline and regular periodic monitoring of liver tests, including serum ALT (SGPT) should be performed for the duration of therapy with FENOGLIDE, and therapy discontinued if enzyme levels persist above three times the normal limit.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s17"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Serum Creatinine
</h2>
<p class="First">Elevations in serum creatinine have been reported in patients on fenofibrate. These elevations tend to return to baseline following discontinuation of fenofibrate. The clinical significance of these observations is unknown. Monitor renal function in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> taking FENOGLIDE. Renal monitoring should also be considered for patients taking FENOGLIDE at risk for <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> such as the elderly and patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s18"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="4098112" conceptname="Biliary sludge">Cholelithiasis</span>
</h2>
<p class="First">Fenofibrate, like clofibrate and gemfibrozil, may increase <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> excretion into the bile, leading to <span class="product-label-link" type="condition" conceptid="4098112" conceptname="Biliary sludge">cholelithiasis</span>. If <span class="product-label-link" type="condition" conceptid="4098112" conceptname="Biliary sludge">cholelithiasis</span> is suspected, gallbladder studies are indicated. FENOGLIDE therapy should be discontinued if <span class="product-label-link" type="condition" conceptid="196456" conceptname="Gallstone">gallstones</span> are found.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s19"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Coumarin Anticoagulants
</h2>
<p class="First">Caution should be exercised when anticoagulants are given in conjunction with FENOGLIDE because of the potentiation of coumarin-type anticoagulants in prolonging the <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time/International Normalized Ratio (PT/INR). To prevent <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> complications, frequent monitoring of PT/INR and dose adjustment of the anticoagulant are recommended until PT/INR has stabilized [<span class="Italics">see Drug Interactions (<a href="#s28">7.1</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s20"></a><a name="section-5.7"></a><p></p>
<h2>5.7 <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span>
</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span> has been reported in patients taking fenofibrate, gemfibrozil, and clofibrate. This occurrence may represent a failure of efficacy in patients with severe <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>, a direct drug effect, or a secondary phenomenon mediated through biliary tract stone or sludge formation with obstruction of the common bile duct.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s21"></a><a name="section-5.8"></a><p></p>
<h2>5.8 Hematologic Changes
</h2>
<p class="First">Mild to moderate hemoglobin, hematocrit, and white blood cell decreases have been observed in patients following initiation of fenofibrate therapy. However, these levels stabilize during long-term administration. <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> have been reported in individuals treated with fenofibrate. Periodic monitoring of red and white blood cell counts are recommended during the first 12 months of FENOGLIDE administration.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s22"></a><a name="section-5.9"></a><p></p>
<h2>5.9 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span>
</h2>
<p class="First">Acute <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> such as <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> requiring patient hospitalization and treatment with steroids have been reported in individuals treated with fenofibrates.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s23"></a><a name="section-5.10"></a><p></p>
<h2>5.10 Venothromboembolic Disease
</h2>
<p class="First">In the FIELD trial, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolus</span> (PE) and <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> (DVT) were observed at higher rates in the fenofibrate than the placebo-treated group. Of 9,795 patients enrolled in FIELD, there were 4,900 in the placebo group and 4,895 in the fenofibrate group. For DVT, there were 48 events (1%) in the placebo group and 67 (1%) in the fenofibrate group (p = 0.074); and for PE, there were 32 (0.7%) events in the placebo group and 53 (1%) in the fenofibrate group (p = 0.022).
</p>
<p>In the Coronary Drug Project, a higher proportion of the clofibrate group experienced definite or suspected fatal or nonfatal <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> or <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span> than the placebo group (5.2% vs. 3.3% at five years; p &lt; 0.01).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e23"></a><a name="section-5.11"></a><p></p>
<h2>5.11 Paradoxical Decreases in HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> Levels
</h2>
<p class="First">There have been postmarketing and clinical trial reports of severe decreases in HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> levels (as low as 2 mg/dL) occurring in diabetic and non-diabetic patients initiated on fibrate therapy. The decrease in HDL-C is mirrored by a decrease in <span class="product-label-link" type="condition" conceptid="4122128" conceptname="Apolipoprotein">apolipoprotein</span> A1. This decrease has been reported to occur within 2 weeks to years after initiation of fibrate therapy. The HDL-C levels remain depressed until fibrate therapy has been withdrawn; the response to withdrawal of fibrate therapy is rapid and sustained. The clinical significance of this decrease in HDL-C is unknown. It is recommended that HDL-C levels be checked within the first few months after initiation of fibrate therapy. If a severely depressed HDL-C level is detected, fibrate therapy should be withdrawn, and the HDL-C level monitored until it has returned to baseline, and fibrate therapy should not be re-initiated.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s24"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s25"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience
</h2>
<p class="First">Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect rates observed in clinical practice.
</p>
<p>Adverse reactions reported by 2% or more of patients treated with fenofibrate and greater than placebo during double-blind, placebo-controlled trials are listed in <a href="#t1">Table 1</a> below. Adverse reactions led to discontinuation of treatment in 5.0% of patients treated with fenofibrate and in 3.0% treated with placebo. Increases in liver function tests were the most frequent events, causing discontinuation of fenofibrate treatment in 1.6% of patients in double-blind trials.
</p>
<a name="t1"></a><table width="100%">
<caption><span>Table 1. Adverse Reactions Reported by 2% or More of Patients Treated with Fenofibrate and Greater than Placebo During the Double-Blind, Placebo-Controlled Trials
</span></caption>
<col align="left" width="59.080%">
<col align="left" width="15.761%">
<col align="left" width="25.158%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="left" valign="middle"><span class="Bold">BODY SYSTEM<br>Adverse Reaction</span></th>
<th class="Botrule Rrule Toprule" align="center" valign="middle"><span class="Bold">Fenofibrate*<br>(N=439)</span></th>
<th class="Botrule Rrule Toprule" align="center" valign="middle"><span class="Bold">Placebo<br>(N=365)</span></th>
</tr></thead>
<tfoot><tr class="First Last"><td align="left" colspan="3" valign="top"><p class="First Footnote">*Dosage equivalent to 130 mg fenofibrate
</p></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule" align="left" valign="middle">BODY AS A WHOLE
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">   <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">4.6%
</td>
<td class="Botrule Rrule" align="center" valign="middle">4.4%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">   <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">3.4%
</td>
<td class="Botrule Rrule" align="center" valign="middle">2.5%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">   <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">3.2%
</td>
<td class="Botrule Rrule" align="center" valign="middle">2.7%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">DIGESTIVE
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">   <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">2.3%
</td>
<td class="Botrule Rrule" align="center" valign="middle">1.9%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">   <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">2.1%
</td>
<td class="Botrule Rrule" align="center" valign="middle">1.4%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">METABOLIC AND NUTRITIONAL<br>DISORDERS
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">   Abnormal Liver Tests
</td>
<td class="Botrule Rrule" align="center" valign="middle">7.5%
</td>
<td class="Botrule Rrule" align="center" valign="middle">1.4%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">   Increased AST
</td>
<td class="Botrule Rrule" align="center" valign="middle">3.4%
</td>
<td class="Botrule Rrule" align="center" valign="middle">0.5%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">   Increased ALT
</td>
<td class="Botrule Rrule" align="center" valign="middle">3.0%
</td>
<td class="Botrule Rrule" align="center" valign="middle">1.6%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">   Increased Creatine Phosphokinase
</td>
<td class="Botrule Rrule" align="center" valign="middle">3.0%
</td>
<td class="Botrule Rrule" align="center" valign="middle">1.4%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">RESPIRATORY
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">   <span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">Respiratory Disorder</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">6.2%
</td>
<td class="Botrule Rrule" align="center" valign="middle">5.5%
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="middle">   <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">2.3%
</td>
<td class="Botrule Rrule" align="center" valign="middle">1.1%
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s26"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience
</h2>
<p class="First">The following adverse reactions have been identified during postapproval use of fenofibrate: <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasms</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, cirrhosis, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, decreases in hematocrit, white blood cell decreases, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, and severely depressed HDLcholesterol levels. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a casual relationship to drug exposure.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s27"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s28"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Coumarin Anticoagulants
</h2>
<p class="First">Caution should be exercised when coumarin anticoagulants are given in conjunction with FENOGLIDE. The dosage of the anticoagulants should be reduced to maintain the PT/INR at the desired level to prevent <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> complications. Frequent PT/INR determinations are advisable until it has been definitely determined that the <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time/INR has stabilized <span class="Italics">[see Warnings and Precautions (<a href="#s19">5.6</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s29"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Immunosuppressants
</h2>
<p class="First">Immunosuppressants such as cyclosporine and tacrolimus can produce <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including FENOGLIDE, there is a risk that an interaction will lead to deterioration of renal function. The benefits and risks of using FENOGLIDE with immunosuppressants and other potentially nephrotoxic agents should be carefully considered, and the lowest effective dose employed and renal function monitored.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s30"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Bile-Acid Binding Resins
</h2>
<p class="First">Since bile acid resins may bind other drugs given concurrently, patients should take FENOGLIDE at least 1 hour before or 4 to 6 hours after a bile acid binding resin to avoid impeding its absorption.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e30"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Colchicine
</h2>
<p class="First">Cases of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, have been reported with fenofibrates co-administered with colchicine, and caution should be exercised when prescribing fenofibrate with colchicine.
</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="s31"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS
</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="s32"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s33"></a><a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Italics">Pregnancy Category C</span>. Safety in pregnant women has not been established. There are no adequate and well controlled studies of fenofibrate in pregnant women. Fenofibrate should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
</p>
<p>In female rats given oral dietary doses of 15, 75, and 300 mg/kg/day of fenofibrate from 15 days prior to mating through weaning, maternal toxicity was observed at 0.3 times the maximum recommended human dose (MRHD), based on body surface area comparisons; mg/m<span class="Sup">2</span>.
</p>
<p>In pregnant rats given oral dietary doses of 14, 127, and 361 mg/kg/day from gestation day 6-15 during the period of organogenesis, adverse developmental findings were not observed at 14 mg/kg/day (less than 1 times the MRHD, based on body surface area comparisons; mg/m<span class="Sup">2</span>). At higher multiples of human doses evidence of maternal toxicity was observed.
</p>
<p>In pregnant rabbits given oral gavage doses of 15, 150, and 300 mg/kg/day from gestation day 6-18 during the period of organogenesis and allowed to deliver, aborted litters were observed at 150 mg/kg/day (10 times the MRHD, based on body surface area comparisons: mg/m<span class="Sup">2</span>). No developmental findings were observed at 15 mg/kg/day (at less than 1 times the MRHD, based on body surface area comparisons; mg/m<span class="Sup">2</span>).
</p>
<p>In pregnant rats given oral dietary doses of 15, 75, and 300 mg/kg/day from gestation day 15 through lactation day 21 (weaning), maternal toxicity was observed at less than 1 times the MRHD, based on body surface area comparisons; mg/m<span class="Sup">2</span>.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s34"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers
</h2>
<p class="First">Fenofibrate should not be used in nursing mothers. A decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s35"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use
</h2>
<p class="First">Safety and efficacy have not been established in pediatric patients.
</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s36"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use
</h2>
<p class="First">Fenofibric acid is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Fenofibric acid exposure is not influenced by age. Since elderly patients have a higher incidence of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, dose selection for the elderly should be made on the basis of renal function <span class="Italics">[</span>see Dosage and Administration (<a href="#s10">2.5</a>) and Clinical Pharmacology <span class="Italics">(<a href="#s43">12.3</a>)</span><span class="Italics">]</span>. Elderly patients with normal renal function should require no dose modifications. Consider monitoring renal function in elderly patients taking FENOGLIDE.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s37"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</h2>
<p class="First">The use of FENOGLIDE should be avoided in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> <span class="Italics">[</span>see Contraindications <span class="Italics">(<a href="#s12">4</a>)</span><span class="Italics">]</span>. Dose reduction is required in patients with mild to moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> [<span class="Italics">see Dosage and Administration
</span><span class="Italics">(<a href="#s9">2.4</a>)
</span><span class="Italics">and Clinical Pharmacology
</span><span class="Italics">(<a href="#s43">12.3</a>)</span>]. Monitoring renal function in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> is recommended.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e37"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>
</h2>
<p class="First">The use of FENOGLIDE has not been evaluated in subjects with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. (<span class="Italics">see Contraindication (<a href="#s12">4</a>) and Clinical Pharmacology (<a href="#s43">12.3</a>)]</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s38"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE
</h1>
<p class="First">There is no specific treatment for <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with FENOGLIDE. General supportive care of the patient is indicated, including monitoring of vital signs and observation of clinical status, should an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> occur. If indicated, elimination of unabsorbed drug should be achieved by <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> or gastric lavage; usual precautions should be observed to maintain the airway. Because fenofibrate is highly bound to plasma proteins, hemodialysis should not be considered.
</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s39"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION
</h1>
<p class="First">FENOGLIDE (fenofibrate) Tablets, is a lipid regulating agent available as tablets for oral administration. Each tablet contains 40 mg or 120 mg fenofibrate. The chemical name for fenofibrate is 2-[4-(4-chlorobenzoyl) phenoxy]-2-methyl-propanoic acid, 1-methylethyl ester with the following structural formula:
</p>
<div class="Figure">
<a name="f01"></a><img alt="Structural Formula
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=35e89d4e-45cf-4374-bf93-fca8d40d783b&amp;name=fen01-0004-01.jpg">
</div>
<p>The empirical formula is C<span class="Sub">20</span>H<span class="Sub">21</span>O<span class="Sub">4</span>Cl and the molecular weight is 360.83; fenofibrate is insoluble in water. The melting point is 79° to 82°C. Fenofibrate is a white solid which is stable under ordinary conditions.
</p>
<p>Inactive Ingredients: Each tablet contains lactose monohydrate, NF; Polyethylene Glycol 6000, NF; Poloxamer 188, NF; and magnesium stearate, NF.
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s40"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY
</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="s41"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action
</h2>
<p class="First">The active moiety of FENOGLIDE is fenofibric acid. The pharmacological effects of fenofibric acid in both animals and humans have been extensively studied through oral administration of fenofibrate.
</p>
<p>The lipid-lowering effects of fenofibric acid seen in clinical practice have been explained <span class="Italics">in vivo</span> in transgenic mice and <span class="Italics">in vitro</span> in human hepatocyte cultures by the activation of peroxisome proliferator activated receptor α (PPARα). Through this mechanism, fenofibrate increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of apoprotein C-III (an inhibitor of lipoprotein lipase activity). The resulting decrease in TG produces an alteration in the size and composition of LDL from small, dense particles (which are thought to be atherogenic due to their susceptibility to oxidation), to large buoyant particles. These larger particles have a greater affinity for <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> receptors and are catabolized rapidly. Activation of PPARα also induces an increase in the synthesis of apoproteins A-I, A-II and HDL-<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>.
</p>
<p>Fenofibrate also reduces serum uric acid levels in hyperuricemic and normal individuals by increasing the urinary excretion of uric acid.
</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="s42"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics
</h2>
<p class="First">A variety of clinical studies have demonstrated that elevated levels of total -C, LDL-C, and <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">apo B</span>, an LDL membrane complex, are risk factors for human <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">atherosclerosis</span>. Similarly, decreased levels of HDL-C and its transport complex, <span class="product-label-link" type="condition" conceptid="4122128" conceptname="Apolipoprotein">apolipoprotein</span> A (apo AI and apo AII) are risk factors for the development of <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">atherosclerosis</span>. Epidemiologic investigations have established that cardiovascular morbidity and mortality vary directly with the level of total-C, LDL-C, and TG, and inversely with the level of HDL-C. The independent effect of raising HDL-C or lowering TG on the risk of cardiovascular morbidity and mortality has not been determined.
</p>
<p>Fenofibric acid, the active metabolite of fenofibrate, produces reductions in TC, LDL-C, <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">apo B</span>, total triglycerides, and triglyceride-rich lipoprotein (VLDL) in treated patients. In addition, treatment with fenofibrate results in increases in HDL and apoproteins apo AI and apo AII.
</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="s43"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics
</h2>
<p class="First">Fenofibrate is a pro-drug of the active chemical moiety fenofibric acid. Fenofibrate is converted by ester hydrolysis in the body to fenofibric acid which is the active constituent measurable in the circulation.
</p>
<p>Plasma concentrations of fenofibric acid after single-dose administration of FENOGLIDE Tablets, 120 mg are equivalent to those of Fenofibrate 130 mg capsules under high-fat conditions.
</p>
<p>A high-fat meal did not affect the fenofibric acid AUC after FENOGLIDE administration but did increase the mean Cmax by 44% compared to fastin<span class="Italics">g</span> conditions.
</p>
<ul class="Disc">
<li>
<span class="Bold">Absorption:</span> The absolute bioavailability of fenofibrate cannot be determined as the compound is virtually insoluble in aqueous media suitable for injection. However, fenofibrate is well absorbed from the gastrointestinal tract. Following oral administration in healthy volunteers, approximately 60% of a single dose of radiolabelled fenofibrate appeared in urine, primarily as fenofibric acid and its glucuronate conjugate, and 25% was excreted in the feces. Peak plasma levels of fenofibric acid from FENOGLIDE occur, on average, within 2 to 3 hours after administration.<br>Doses of three FENOGLIDE (fenofibrate) Tablets, 40 mg are considered to be equivalent to single doses of FENOGLIDE (fenofibrate) Tablets, 120 mg.
</li>
<li>
<span class="Bold">Distribution:</span> In healthy volunteers, steady-state plasma levels of fenofibric acid were shown to be achieved within a week of dosing and did not demonstrate accumulation across time following multiple dose administration. Serum protein binding was approximately 99% in normal and hyperlipidemic subjects.
</li>
<li>
<span class="Bold">Metabolism:</span> Following oral administration, fenofibrate is rapidly hydrolyzed by esterases to the active metabolite, fenofibric acid; no unchanged fenofibrate is detected in plasma.<br>Fenofibric acid is primarily conjugated with glucuronic acid and then excreted in urine. A small amount of fenofibric acid is reduced at the carbonyl moiety to a benzhydrol metabolite which is, in turn, conjugated with glucuronic acid and excreted in urine.<br><span class="Italics">In vivo</span> metabolism data indicate that neither fenofibrate nor fenofibric acid undergo oxidative metabolism (e.g., cytochrome P450) to a significant extent.
</li>
<li>
<span class="Bold">Elimination:</span> After absorption, fenofibrate is mainly excreted in the urine in the form of metabolites, primarily fenofibric acid and fenofibric acid glucuronide. After administration of radiolabelled fenofibrate, approximately 60% of the dose appeared in the urine and 25% was excreted in the feces. <br>Fenofibric acid from FENOGLIDE is eliminated with a half-life of 23 hours, allowing once daily dosing.
</li>
<li>
<span class="Bold">Geriatrics:</span> In elderly volunteers 77 to 87 years of age, the oral clearance of fenofibric acid following a single oral dose of fenofibrate was 1.2 L/h, which compares to 1.1 L/h in young adults. This indicates that a similar dosage regimen can be used in the elderly, without increasing accumulation of the drug or metabolites <span class="Italics">[see Dosage and Administration (<a href="#s10">2.5</a>) and Use in Specific Populations (<a href="#s36">8.5</a>)].</span>
</li>
<li>
<span class="Bold">Pediatrics:</span> The pharmacokinetics of FENOGLIDE has not been studied in pediatric populations.
</li>
<li>
<span class="Bold">Gender:</span> No pharmacokinetic difference between males and females has been observed for fenofibrate.
</li>
<li>
<span class="Bold">Race:</span> The influence of race on the pharmacokinetics of fenofibrate has not been studied; however, fenofibrate is not metabolized by enzymes known for exhibiting inter-ethnic variability.
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>:</span> The pharmacokinetics of fenofibric acid was examined in patients with mild, moderate, and severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance [CrCl] ≤ 30 mL/min or estimated glomerular filtration rate [eGFR] &lt; 30 mL/min/1.73m<span class="Sup">2</span>) showed 2.7-fold increase in exposure for fenofibric acid and increased accumulation of fenofibric acid during chronic dosing compared to that of healthy subjects. Patients with mild to moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CrCl 30-80 mL/min or eGFR 30-59 mL/min/1.73m<span class="Sup">2</span>) had similar exposure but an increase in the half-life for fenofibric acid compared to that of healthy subjects. Based on these findings, the use of FENOGLIDE should be avoided in patients who have severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and dose reduction is required in patients having mild to moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. [See Dosage and Administration (<a href="#s9">2.4</a>).]
</li>
<li>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>:</span> No pharmacokinetic studies have been conducted in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
<p><span class="Bold">Drug-Drug Interactions:
</span><span class="Italics">In vitro</span> studies using human liver microsomes indicate that fenofibrate and fenofibric acid are not inhibitors of cytochrome (CYP) P450 isoforms CYP3A4, CYP2D6, CYP2E1, or CYP1A2. They are weak inhibitors of CYP2C8, CYP2C19 and CYP2A6, and mild-to-moderate inhibitors of CYP2C9 at therapeutic concentrations.</p>
<p><a href="#t2">Table 2</a> describes the effects of co-administered drugs on fenofibric acidsystemic exposure.  <a href="#t3">Table 3</a> describes the effects of co-administered fenofibrate or fenofibric acid on other drugs systemic exposure.
</p>
</li>
</ul>
<a name="t2"></a><table width="100%">
<caption><span>Table 2. Effects of Co-Administered Drugs on Fenofibric Acid Systemic Exposure from Fenofibrate Administration
</span></caption>
<col align="left" width="12.500%">
<col align="left" width="29.680%">
<col align="left" width="32.380%">
<col align="left" width="12.720%">
<col align="left" width="12.720%">
<tfoot>
<tr class="First"><td align="left" colspan="5" valign="top"><p class="First Footnote"><span class="Sup">1</span> TriCor (fenofibrate) oral tablet
</p></td></tr>
<tr class="Last"><td class="Botrule" align="left" colspan="5" valign="top"><p class="First Footnote"><span class="Sup">2</span> TriCor (fenofibrate) oral micronized capsule
</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="left" valign="top">Co-Administered<br>Drug
</td>
<td class="Toprule" align="left" valign="top">Dosage Regimen of Co- Administered Drug
</td>
<td class="Toprule" align="left" valign="top">Dosage Regimen of<br>Fenofibrate
</td>
<td class="Toprule" align="left" colspan="2" valign="top">Changes in Fenofibric Acid Exposure
</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top">AUC
</td>
<td class="Botrule" align="left" valign="top">C<span class="Sub">max</span>
</td>
</tr>
<tr><td align="left" colspan="5" valign="top"><span class="Italics">Lipid-lowering agents</span></td></tr>
<tr>
<td align="left" valign="top">Atorvastatin
</td>
<td align="left" valign="top">20 mg once daily for 10 days
</td>
<td align="left" valign="top">Fenofibrate 160 mg<span class="Sup">1</span> once daily for 10 days
</td>
<td align="left" valign="top">↓2%
</td>
<td align="left" valign="top">↓4%
</td>
</tr>
<tr>
<td align="left" valign="top">Pravastatin
</td>
<td align="left" valign="top">40 mg as a single dose
</td>
<td align="left" valign="top">Fenofibrate 3 x 67 mg<span class="Sup">2</span> as a single dose
</td>
<td align="left" valign="top">↓1%
</td>
<td align="left" valign="top">↓2%
</td>
</tr>
<tr>
<td align="left" valign="top">Fluvastatin
</td>
<td align="left" valign="top">40 mg as a single dose
</td>
<td align="left" valign="top">Fenofibrate 160 mg<span class="Sup">1</span> as a single dose
</td>
<td align="left" valign="top">↓2%
</td>
<td align="left" valign="top">↓10%
</td>
</tr>
<tr>
<td align="left" colspan="4" valign="top"><span class="Italics">Anti-diabetic agents</span></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Glimepiride
</td>
<td align="left" valign="top">1 mg as a single dose
</td>
<td align="left" valign="top">Fenofibrate 145 mg<span class="Sup">1</span> once daily for 10 days
</td>
<td align="left" valign="top">↑1%
</td>
<td align="left" valign="top">↓1%
</td>
</tr>
<tr>
<td align="left" valign="top">Metformin
</td>
<td align="left" valign="top">850 mg three times daily for 10 days
</td>
<td align="left" valign="top">Fenofibrate 54 mg<span class="Sup">1</span> three times daily for 10 days
</td>
<td align="left" valign="top">↓9%
</td>
<td align="left" valign="top">↓6%
</td>
</tr>
<tr class="Last">
<td align="left" valign="top">Rosiglitazone
</td>
<td align="left" valign="top">8 mg once daily for 5 days
</td>
<td align="left" valign="top">Fenofibrate 145 mg<span class="Sup">1</span> once daily for 14 days
</td>
<td align="left" valign="top">↑10%
</td>
<td align="left" valign="top">↑3%
</td>
</tr>
</tbody>
</table>
<a name="t3"></a><table width="100%">
<caption><span>Table 3. Effects of Fenofibrate Co-Administration on Systemic Exposure of Other Drugs
</span></caption>
<col align="left" width="34.173%">
<col align="left" width="34.093%">
<col align="left" width="21.896%">
<col align="left" width="4.919%">
<col align="left" width="4.919%">
<tfoot>
<tr class="First"><td align="left" colspan="5" valign="top"><p class="First Footnote"><span class="Sup">1</span> TriCor (fenofibrate) oral tablet
</p></td></tr>
<tr class="Last"><td class="Botrule" align="left" colspan="5" valign="top"><p class="First Footnote"><span class="Sup">2</span> TriCor (fenofibrate) oral micronized capsule
</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="left" valign="top">Dosage Regimen of<br>Fenofibrate
</td>
<td class="Toprule" align="left" valign="top">Dosage Regimen of<br>Co-Administered Drug
</td>
<td class="Toprule" align="left" colspan="3" valign="top">Change in Co-Administered Drug Exposure
</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top">Analyte
</td>
<td class="Botrule" align="left" valign="top">AUC
</td>
<td class="Botrule" align="left" valign="top">C<span class="Sub">max</span>
</td>
</tr>
<tr><td align="left" colspan="5" valign="top"><span class="Italics">Lipid-lowering agents</span></td></tr>
<tr>
<td align="left" valign="top">Fenofibrate 160 mg<span class="Sup">1</span> once daily for 10 days
</td>
<td align="left" valign="top">Atorvastatin, 20 mg once daily for 10 days
</td>
<td align="left" valign="top">Atorvastatin
</td>
<td align="left" valign="top">↓17%
</td>
<td align="left" valign="top">0%
</td>
</tr>
<tr>
<td align="left" valign="top">Fenofibrate 3 x 67 mg<span class="Sup">2</span> as a single dose
</td>
<td align="left" valign="top">Pravastatin, 40 mg as a single dose
</td>
<td align="left" valign="top">Pravastatin
</td>
<td align="left" valign="top">↑13%
</td>
<td align="left" valign="top">↑13%
</td>
</tr>
<tr>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top">3α-Hydroxyl-iso-pravastatin
</td>
<td align="left" valign="top">↑26%
</td>
<td align="left" valign="top">↑29%
</td>
</tr>
<tr>
<td align="left" valign="top">Fenofibrate 160 mg<span class="Sup">1</span> as a single dose
</td>
<td align="left" valign="top">Fluvastatin, 40 mg as a single dose
</td>
<td align="left" valign="top">(+)-3R, 5S-Fluvastatin
</td>
<td align="left" valign="top">↑15%
</td>
<td align="left" valign="top">↑16%
</td>
</tr>
<tr>
<td align="left" colspan="4" valign="top"><span class="Italics">Anti-diabetic agents</span></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Fenofibrate 145 mg<span class="Sup">1</span> once daily for 10 days
</td>
<td align="left" valign="top">Glimepiride, 1 mg as a single dose
</td>
<td align="left" valign="top">Glimepiride
</td>
<td align="left" valign="top">↑35%
</td>
<td align="left" valign="top">↑18%
</td>
</tr>
<tr>
<td align="left" valign="top">Fenofibrate 54 mg<span class="Sup">1</span> three times daily for 10 days
</td>
<td align="left" valign="top">Metformin, 850 mg three times daily for 10 days
</td>
<td align="left" valign="top">Metformin
</td>
<td align="left" valign="top">↑3%
</td>
<td align="left" valign="top">↑6%
</td>
</tr>
<tr class="Last">
<td align="left" valign="top">Fenofibrate 145 mg<span class="Sup">1</span> once daily for 14 days
</td>
<td align="left" valign="top">Rosiglitazone, 8 mg once daily for 5 days
</td>
<td align="left" valign="top">Rosiglitazone
</td>
<td align="left" valign="top">↑6%
</td>
<td align="left" valign="top">↓1%
</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="s44"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY
</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="s45"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</h2>
<p class="First">Two dietary carcinogenicity studies have been conducted in rats with fenofibrate. In the first 24-month study, Wistar rats were dosed with fenofibrate at 10, 45, and 200 mg/kg/day, approximately 0.3, 1, and 6 times the maximum recommended human dose (MRHD), based on body surface area comparisons (mg/m<span class="Sup">2</span>). At a dose of 200 mg/kg/day (at 6 times the MRHD), the incidence of <span class="product-label-link" type="condition" conceptid="201519" conceptname="Primary malignant neoplasm of liver">liver carcinomas</span> was significantly increased in both sexes. A statistically significant increase in pancreatic carcinomas was observed in males at 1 and 6 times the MRHD; an increase in <span class="product-label-link" type="condition" conceptid="4243445" conceptname="Benign neoplasm of pancreas">pancreatic adenomas</span> and benign testicular interstitial cell tumors was observed at 6 times the MRHD in males. In a second 24-month rat carcinogenicity study in a different <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> of rats (Sprague-Dawley), doses of 10 and 60 mg/kg/day (0.3 and 2 times the MRHD) produced significant increases in the incidence of pancreatic acinar <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> in both sexes and increases in testicular interstitial cell tumors in males at 2 times the MRHD.
</p>
<p>A 117-week carcinogenicity study was conducted in rats comparing three drugs: fenofibrate 10 and 60 mg/kg/day (0.3 and 2 times the MRHD), clofibrate (400 mg/kg/day; 2 times the human dose), and gemfibrozil (250 mg/kg/day; 2 times the human dose, based on mg/m<span class="Sup">2</span> surface area). Fenofibrate increased pancreatic acinar <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> in both sexes. Clofibrate increased hepatocellular carcinoma and pancreatic acinar <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> in males and hepatic neoplastic <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodules</span> in females. Gemfibrozil increased hepatic neoplastic <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodules</span> in males and females, while all three drugs increased testicular interstitial cell tumors in males.
</p>
<p>In a 21-month study in CF-1 mice, fenofibrate 10, 45, and 200 mg/kg/day (approximately 0.2, 1, and 3 times the MRHD on the basis of mg/m<span class="Sup">2</span> surface area) significantly increased the <span class="product-label-link" type="condition" conceptid="201519" conceptname="Primary malignant neoplasm of liver">liver carcinomas</span> in both sexes at 3 times the MRHD. In a second 18-month study at 10, 60, and 200 mg/kg/day, fenofibrate significantly increased the <span class="product-label-link" type="condition" conceptid="201519" conceptname="Primary malignant neoplasm of liver">liver carcinomas</span> in male mice and liver <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> in female mice at 3 times the MRHD.
</p>
<p>Electron microscopy studies have demonstrated peroxisomal proliferation following fenofibrate administration to the rat. An adequate study to test for peroxisome proliferation in humans has not been done, but changes in peroxisome morphology and numbers have been observed in humans after treatment with other members of the fibrate class when liver biopsies were compared before and after treatment in the same individual.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s46"></a><a name="section-12.1.1"></a><p></p>
<p class="First"><span class="Bold">Mutagenesis:</span> Fenofibrate has been demonstrated to be devoid of mutagenic potential in the following tests: Ames, mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>, chromosomal aberration and unscheduled DNA synthesis in primary rat hepatocytes.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s47"></a><a name="section-12.1.2"></a><p></p>
<p class="First"><span class="Bold">Impairment of Fertility:</span> In fertility studies, rats were given oral dietary doses of fenofibrate, males received 61 days prior to mating and females 15 days prior to mating through weaning which resulted in no adverse effect on fertility at doses up to 300 mg/kg/day (~10 times the MRHD, based on mg/m<span class="Sup">2</span> surface area comparisons).
</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s48"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s49"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Primary <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">Hypercholesterolemia</span> (Heterozygous Familial and Nonfamilial) and Mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span>
</h2>
<p class="First">The effects of fenofibrate at a dose equivalent to 120 mg FENOGLIDE per day were assessed from four randomized, placebo-controlled, double-blind, parallel-group studies including patients with the following mean baseline lipid values: total-C 306.9 mg/dL; LDL-C 213.8 mg/dL; HDL-C 52.3 mg/dL; and triglycerides 191.0 mg/dL. Fenofibrate therapy lowered LDL-C, Total-C, and the LDL-C/HDL-C ratio. Fenofibrate therapy also lowered triglycerides and raised HDL-C (see <a href="#t4">Table 4</a>).
</p>
<a name="t4"></a><table width="100%">
<caption><span>Table 4. Mean Percent Change in Lipid Parameters at End of Treatment*
</span></caption>
<col align="left" width="54.189%">
<col align="left" width="11.738%">
<col align="left" width="11.738%">
<col align="left" width="10.598%">
<col align="left" width="11.738%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="left" valign="middle"><span class="Bold">Treatment Group</span></th>
<th class="Botrule Rrule Toprule" align="left" valign="middle"><span class="Bold">Total-C</span></th>
<th class="Botrule Rrule Toprule" align="left" valign="middle"><span class="Bold">LDL-C</span></th>
<th class="Botrule Rrule Toprule" align="left" valign="middle"><span class="Bold">HDL-C</span></th>
<th class="Botrule Rrule Toprule" align="left" valign="middle"><span class="Bold">TG</span></th>
</tr></thead>
<tfoot>
<tr class="First"><td align="left" colspan="5" valign="top"><p class="First Footnote">* Duration of study treatment was 3 to 6 months.
</p></td></tr>
<tr class="Last"><td align="left" colspan="5" valign="top"><p class="First Footnote">† p=&lt;0.05 vs. placebo
</p></td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule" align="left" valign="middle">Pooled Cohort
</td>
<td class="Botrule Rrule" align="left" valign="middle"></td>
<td class="Botrule Rrule" align="left" valign="middle"></td>
<td class="Botrule Rrule" align="left" valign="middle"></td>
<td class="Botrule Rrule" align="left" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">   Mean baseline lipid values (n=646)
</td>
<td class="Botrule Rrule" align="left" valign="middle">306.9 mg/dL
</td>
<td class="Botrule Rrule" align="left" valign="middle">213.8 mg/dL
</td>
<td class="Botrule Rrule" align="left" valign="middle">52.3 mg/dL
</td>
<td class="Botrule Rrule" align="left" valign="middle">191.0 mg/dL
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"> All FEN (n=361)
</td>
<td class="Botrule Rrule" align="left" valign="middle">-18.7%†
</td>
<td class="Botrule Rrule" align="left" valign="middle">-20.6%†
</td>
<td class="Botrule Rrule" align="left" valign="middle">+11.0%†
</td>
<td class="Botrule Rrule" align="left" valign="middle">-28.9%†
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"> Placebo (n=285)
</td>
<td class="Botrule Rrule" align="left" valign="middle">-0.4%
</td>
<td class="Botrule Rrule" align="left" valign="middle">-2.2%
</td>
<td class="Botrule Rrule" align="left" valign="middle">+0.7%
</td>
<td class="Botrule Rrule" align="left" valign="middle">+7.7%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Baseline LDL-C &gt;160 mg/dL and TG &lt;150 mg/dL (Type IIa)
</td>
<td class="Botrule Rrule" align="left" valign="middle"></td>
<td class="Botrule Rrule" align="left" valign="middle"></td>
<td class="Botrule Rrule" align="left" valign="middle"></td>
<td class="Botrule Rrule" align="left" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"> Mean baseline lipid values (n=334)
</td>
<td class="Botrule Rrule" align="left" valign="middle">307.7 mg/dL
</td>
<td class="Botrule Rrule" align="left" valign="middle">227.7 mg/dL
</td>
<td class="Botrule Rrule" align="left" valign="middle">58.1 mg/dL
</td>
<td class="Botrule Rrule" align="left" valign="middle">101.7 mg/dL
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"> All FEN (n=193)
</td>
<td class="Botrule Rrule" align="left" valign="middle">-22.4%†
</td>
<td class="Botrule Rrule" align="left" valign="middle">-31.4%†
</td>
<td class="Botrule Rrule" align="left" valign="middle">+9.8%†
</td>
<td class="Botrule Rrule" align="left" valign="middle">-23.5%†
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"> Placebo (n=141)
</td>
<td class="Botrule Rrule" align="left" valign="middle">+0.2%
</td>
<td class="Botrule Rrule" align="left" valign="middle">-2.2%
</td>
<td class="Botrule Rrule" align="left" valign="middle">+2.6%
</td>
<td class="Botrule Rrule" align="left" valign="middle">+11.7%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Baseline LDL-C &gt;160 mg/dL and TG ≥150 mg/dL (Type IIb)
</td>
<td class="Botrule Rrule" align="left" valign="middle"></td>
<td class="Botrule Rrule" align="left" valign="middle"></td>
<td class="Botrule Rrule" align="left" valign="middle"></td>
<td class="Botrule Rrule" align="left" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"> Mean baseline lipid values (n=242)
</td>
<td class="Botrule Rrule" align="left" valign="middle">312.8 mg/dL
</td>
<td class="Botrule Rrule" align="left" valign="middle">219.8 mg/dL
</td>
<td class="Botrule Rrule" align="left" valign="middle">46.7 mg/dL
</td>
<td class="Botrule Rrule" align="left" valign="middle">231.9 mg/dL
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"> All FEN (n=126)
</td>
<td class="Botrule Rrule" align="left" valign="middle">-16.8%†
</td>
<td class="Botrule Rrule" align="left" valign="middle">-20.1%†
</td>
<td class="Botrule Rrule" align="left" valign="middle">+14.6%†
</td>
<td class="Botrule Rrule" align="left" valign="middle">-35.9%†
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="middle"> Placebo (n=116)
</td>
<td class="Botrule Rrule" align="left" valign="middle">-3.0%
</td>
<td class="Botrule Rrule" align="left" valign="middle">-6.6%
</td>
<td class="Botrule Rrule" align="left" valign="middle">+2.3%
</td>
<td class="Botrule Rrule" align="left" valign="middle">+0.9%
</td>
</tr>
</tbody>
</table>
<p>In a subset of the subjects, measurements of <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">apo B</span> were conducted. Fenofibrate treatment significantly reduced <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">apo B</span> from baseline to endpoint as compared with placebo (-25.1% vs. 2.4%, p&lt;0.0001, n=213 and 143 respectively).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s50"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Severe <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span>
</h2>
<p class="First">The effects of fenofibrate on serum triglycerides were studied in two randomized, double-blind, placebo-controlled clinical trials of 147 hypertriglyceridemic patients. Patients were treated for eight weeks under protocols that differed only in that one entered patients with baseline TG levels of 500 to 1500 mg/dL, and the other TG levels of 350 to 500 mg/dL. In patients with <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span> and normal cholesterolemia with or without hyperchylomicronemia, treatment with fenofibrate at dosages equivalent to 120 mg FENOGLIDE (fenofibrate) Tablets per day decreased primarily very low density lipoprotein (VLDL) triglycerides and VLDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>. Treatment of patients with elevated triglycerides often results in an increase of LDL-C (see <a href="#t5">Table 5</a>).
</p>
<a name="t5"></a><table width="100%">
<caption><span>Table 5. Effects of Fenofibrate in Patients With Severe <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span>
</span></caption>
<col align="left" width="37.440%">
<col align="left" width="2.844%">
<col align="left" width="8.788%">
<col align="left" width="9.032%">
<col align="left" width="10.621%">
<col align="left" width="2.833%">
<col align="left" width="8.788%">
<col align="left" width="9.032%">
<col align="left" width="10.621%">
<tfoot><tr class="First Last"><td align="left" colspan="9" valign="top"><p class="First Footnote">*=p&lt;0.05 vs. placebo
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle"><span class="Bold">Study 1</span></td>
<td class="Botrule Rrule Toprule" align="left" colspan="4" valign="middle"><span class="Bold">Placebo</span></td>
<td class="Botrule Rrule Toprule" align="left" colspan="4" valign="middle"><span class="Bold">Fenofibrate</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Baseline TG levels 350 to 499 mg/dL
</td>
<td class="Botrule Rrule" align="left" valign="middle">N
</td>
<td class="Botrule Rrule" align="left" valign="middle">Baseline<br>(Mean)
</td>
<td class="Botrule Rrule" align="left" valign="middle">Endpoint<br>(Mean)
</td>
<td class="Botrule Rrule" align="left" valign="middle">% Change<br>(Mean)
</td>
<td class="Botrule Rrule" align="left" valign="middle">N
</td>
<td class="Botrule Rrule" align="left" valign="middle">Baseline<br>(Mean)
</td>
<td class="Botrule Rrule" align="left" valign="middle">Endpoint<br>(Mean)
</td>
<td class="Botrule Rrule" align="left" valign="middle">% Change<br>(Mean)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Triglycerides
</td>
<td class="Botrule Rrule" align="left" valign="middle">28
</td>
<td class="Botrule Rrule" align="left" valign="middle">449
</td>
<td class="Botrule Rrule" align="left" valign="middle">450
</td>
<td class="Botrule Rrule" align="left" valign="middle">-0.5
</td>
<td class="Botrule Rrule" align="left" valign="middle">27
</td>
<td class="Botrule Rrule" align="left" valign="middle">432
</td>
<td class="Botrule Rrule" align="left" valign="middle">223
</td>
<td class="Botrule Rrule" align="left" valign="middle">-46.2*
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">VLDL Triglycerides
</td>
<td class="Botrule Rrule" align="left" valign="middle">19
</td>
<td class="Botrule Rrule" align="left" valign="middle">367
</td>
<td class="Botrule Rrule" align="left" valign="middle">350
</td>
<td class="Botrule Rrule" align="left" valign="middle">2.7
</td>
<td class="Botrule Rrule" align="left" valign="middle">19
</td>
<td class="Botrule Rrule" align="left" valign="middle">350
</td>
<td class="Botrule Rrule" align="left" valign="middle">178
</td>
<td class="Botrule Rrule" align="left" valign="middle">-44.1*
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span>
</td>
<td class="Botrule Rrule" align="left" valign="middle">28
</td>
<td class="Botrule Rrule" align="left" valign="middle">255
</td>
<td class="Botrule Rrule" align="left" valign="middle">261
</td>
<td class="Botrule Rrule" align="left" valign="middle">2.8
</td>
<td class="Botrule Rrule" align="left" valign="middle">27
</td>
<td class="Botrule Rrule" align="left" valign="middle">252
</td>
<td class="Botrule Rrule" align="left" valign="middle">227
</td>
<td class="Botrule Rrule" align="left" valign="middle">-9.1*
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span>
</td>
<td class="Botrule Rrule" align="left" valign="middle">28
</td>
<td class="Botrule Rrule" align="left" valign="middle">35
</td>
<td class="Botrule Rrule" align="left" valign="middle">36
</td>
<td class="Botrule Rrule" align="left" valign="middle">4
</td>
<td class="Botrule Rrule" align="left" valign="middle">27
</td>
<td class="Botrule Rrule" align="left" valign="middle">34
</td>
<td class="Botrule Rrule" align="left" valign="middle">40
</td>
<td class="Botrule Rrule" align="left" valign="middle">19.6*
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span>
</td>
<td class="Botrule Rrule" align="left" valign="middle">28
</td>
<td class="Botrule Rrule" align="left" valign="middle">120
</td>
<td class="Botrule Rrule" align="left" valign="middle">129
</td>
<td class="Botrule Rrule" align="left" valign="middle">12
</td>
<td class="Botrule Rrule" align="left" valign="middle">27
</td>
<td class="Botrule Rrule" align="left" valign="middle">128
</td>
<td class="Botrule Rrule" align="left" valign="middle">137
</td>
<td class="Botrule Rrule" align="left" valign="middle">14.5
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">VLDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span>
</td>
<td class="Botrule Rrule" align="left" valign="middle">27
</td>
<td class="Botrule Rrule" align="left" valign="middle">99
</td>
<td class="Botrule Rrule" align="left" valign="middle">99
</td>
<td class="Botrule Rrule" align="left" valign="middle">5.8
</td>
<td class="Botrule Rrule" align="left" valign="middle">27
</td>
<td class="Botrule Rrule" align="left" valign="middle">92
</td>
<td class="Botrule Rrule" align="left" valign="middle">46
</td>
<td class="Botrule Rrule" align="left" valign="middle">-44.7*
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold">Study 2</span></td>
<td class="Botrule Rrule" align="left" colspan="4" valign="middle"><span class="Bold">Placebo</span></td>
<td class="Botrule Rrule" align="left" colspan="4" valign="middle"><span class="Bold">Fenofibrate</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Baseline TG levels 500 to 1500 mg/dL
</td>
<td class="Botrule Rrule" align="left" valign="middle">N
</td>
<td class="Botrule Rrule" align="left" valign="middle">Baseline<br>(Mean)
</td>
<td class="Botrule Rrule" align="left" valign="middle">Endpoint<br>(Mean)
</td>
<td class="Botrule Rrule" align="left" valign="middle">% Change<br>(Mean)
</td>
<td class="Botrule Rrule" align="left" valign="middle">N
</td>
<td class="Botrule Rrule" align="left" valign="middle">Baseline<br>(Mean)
</td>
<td class="Botrule Rrule" align="left" valign="middle">Endpoint<br>(Mean)
</td>
<td class="Botrule Rrule" align="left" valign="middle">% Change<br>(Mean)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Triglycerides
</td>
<td class="Botrule Rrule" align="left" valign="middle">44
</td>
<td class="Botrule Rrule" align="left" valign="middle">710
</td>
<td class="Botrule Rrule" align="left" valign="middle">750
</td>
<td class="Botrule Rrule" align="left" valign="middle">7.2
</td>
<td class="Botrule Rrule" align="left" valign="middle">48
</td>
<td class="Botrule Rrule" align="left" valign="middle">726
</td>
<td class="Botrule Rrule" align="left" valign="middle">308
</td>
<td class="Botrule Rrule" align="left" valign="middle">-54.5*
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">VLDL Triglycerides
</td>
<td class="Botrule Rrule" align="left" valign="middle">29
</td>
<td class="Botrule Rrule" align="left" valign="middle">537
</td>
<td class="Botrule Rrule" align="left" valign="middle">571
</td>
<td class="Botrule Rrule" align="left" valign="middle">18.7
</td>
<td class="Botrule Rrule" align="left" valign="middle">33
</td>
<td class="Botrule Rrule" align="left" valign="middle">543
</td>
<td class="Botrule Rrule" align="left" valign="middle">205
</td>
<td class="Botrule Rrule" align="left" valign="middle">-50.6*
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span>
</td>
<td class="Botrule Rrule" align="left" valign="middle">44
</td>
<td class="Botrule Rrule" align="left" valign="middle">272
</td>
<td class="Botrule Rrule" align="left" valign="middle">271
</td>
<td class="Botrule Rrule" align="left" valign="middle">0.4
</td>
<td class="Botrule Rrule" align="left" valign="middle">48
</td>
<td class="Botrule Rrule" align="left" valign="middle">261
</td>
<td class="Botrule Rrule" align="left" valign="middle">223
</td>
<td class="Botrule Rrule" align="left" valign="middle">-13.8*
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span>
</td>
<td class="Botrule Rrule" align="left" valign="middle">44
</td>
<td class="Botrule Rrule" align="left" valign="middle">27
</td>
<td class="Botrule Rrule" align="left" valign="middle">28
</td>
<td class="Botrule Rrule" align="left" valign="middle">5.0
</td>
<td class="Botrule Rrule" align="left" valign="middle">48
</td>
<td class="Botrule Rrule" align="left" valign="middle">30
</td>
<td class="Botrule Rrule" align="left" valign="middle">36
</td>
<td class="Botrule Rrule" align="left" valign="middle">22.9*
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span>
</td>
<td class="Botrule Rrule" align="left" valign="middle">42
</td>
<td class="Botrule Rrule" align="left" valign="middle">100
</td>
<td class="Botrule Rrule" align="left" valign="middle">90
</td>
<td class="Botrule Rrule" align="left" valign="middle">-4.2
</td>
<td class="Botrule Rrule" align="left" valign="middle">45
</td>
<td class="Botrule Rrule" align="left" valign="middle">103
</td>
<td class="Botrule Rrule" align="left" valign="middle">131
</td>
<td class="Botrule Rrule" align="left" valign="middle">45.0*
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="middle">VLDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span>
</td>
<td class="Botrule Rrule" align="left" valign="middle">42
</td>
<td class="Botrule Rrule" align="left" valign="middle">137
</td>
<td class="Botrule Rrule" align="left" valign="middle">142
</td>
<td class="Botrule Rrule" align="left" valign="middle">11.0
</td>
<td class="Botrule Rrule" align="left" valign="middle">45
</td>
<td class="Botrule Rrule" align="left" valign="middle">126
</td>
<td class="Botrule Rrule" align="left" valign="middle">54
</td>
<td class="Botrule Rrule" align="left" valign="middle">-49.4*
</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s51"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING
</h1>
<p class="First">FENOGLIDE (fenofibrate) Tablets 40 mg, are white to off-white oval tablets debossed "FLO" on one side and blank on the other side.
</p>
<p>Bottle of 90 tablets, NDC 68012-490-90.
</p>
<p>Fennoglide (fenofibrate) Tablets 120 mg are white to off-white oval tablets debossed "FHI" on one side and blank on the other side.
</p>
<p>Bottle of 90 tablets. NDC 68012-495-90
</p>
<p>Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F)
</p>
<p>[See USP Controlled Room Temperature].
</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s52"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION
</h1>
<p class="First">Patients should be advised:
</p>
<ul class="Disc">
<li>of the potential benefits and risks of FENOGLIDE
</li>
<li>not to use FENOGLIDE if there is a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to fenofibrate or fenofibric acid.
</li>
<li>that if they are taking coumarin anticoagulants, FENOGLIDE may increase their anticoagulant effect, and increased monitoring may be necessary.
</li>
<li>of medications that should not be taken in combination with FENOGLIDE.
</li>
<li>to continue to follow an appropriate lipid-modifying diet while taking FENOGLIDE.
</li>
<li>to take FENOGLIDE once daily, without regard to food, at the prescribed dose, swallowing each tablet whole.
</li>
<li>to inform their physician of all medications, supplements, and herbal preparations they are taking and any change to their medical condition. Patients should also be advised to inform their physicians prescribing a new medication that they are taking FENOGLIDE.
</li>
<li>to inform their physician of any <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>; onset of <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>; or any other new symptoms.
</li>
</ul>
<p>Distributed by:<br>Santarus, Inc.<br>San Diego, CA 92130
</p>
<p>FENOGLIDE® is a registered trademark of Santarus, Inc.
</p>
<p>U.S. Patent Nos. 7,658,944, 8,124,125 and 8,481,078.

</p>
<p>S-0060B
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s53"></a><a name="section-16"></a><p></p>
<p class="First"><span class="Bold">Bottle LABEL – PRINCIPAL DISPLAY PANEL 40MG</span></p>
<p>NDC 68012-490-90<br>90 Tablets<br>Rx Only<br>Fenoglide<span class="Sup">® </span><br>(fenofibrate)<br>tablets<br>40 mg
</p>
<div class="Figure">
<a name="f02"></a><img alt="Bottle LABEL – PRINCIPAL DISPLAY PANEL 40MG
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=35e89d4e-45cf-4374-bf93-fca8d40d783b&amp;name=fen01-0004-02.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s54"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">Bottle LABEL – PRINCIPAL DISPLAY PANEL 120MG</span></p>
<p>NDC 68012-495-90<br>90 Tablets
</p>
<p>Rx only
</p>
<p>Fenoglide<span class="Sup">® </span><br>(fenofibrate)<br>tablets<br>120 mg
</p>
<div class="Figure">
<a name="f03"></a><img alt="Bottle LABEL – PRINCIPAL DISPLAY PANEL 120MG
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=35e89d4e-45cf-4374-bf93-fca8d40d783b&amp;name=fen01-0004-03.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>FENOGLIDE 		
					</strong><br><span class="contentTableReg">fenofibrate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:68012-490</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>fenofibrate</strong> (fenofibrate) </td>
<td class="formItem">fenofibrate</td>
<td class="formItem">40 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactose monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Polyethylene Glycol 6000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Poloxamer 188</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white (white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (OVAL) </td>
<td class="formLabel">Size</td>
<td class="formItem">13mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">FLO
</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:68012-490-90</td>
<td class="formItem">90  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022118</td>
<td class="formItem">11/18/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>FENOGLIDE 		
					</strong><br><span class="contentTableReg">fenofibrate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:68012-495</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>fenofibrate</strong> (fenofibrate) </td>
<td class="formItem">fenofibrate</td>
<td class="formItem">120 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactose monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Polyethylene Glycol 6000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Poloxamer 188</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white (white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (OVAL) </td>
<td class="formLabel">Size</td>
<td class="formItem">18mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">FHI
</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:68012-495-90</td>
<td class="formItem">90  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:68012-495-07</td>
<td class="formItem">6  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">7  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022118</td>
<td class="formItem">11/18/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Santarus, Inc.
							(104286369)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Catalent Pharma Solutions</td>
<td class="formItem"></td>
<td class="formItem">829672745</td>
<td class="formItem">MANUFACTURE(68012-490, 68012-495)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ChemAgis Ltd</td>
<td class="formItem"></td>
<td class="formItem">600077101</td>
<td class="formItem">API MANUFACTURE(68012-490, 68012-495)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Packaging Coordinators Inc</td>
<td class="formItem"></td>
<td class="formItem">078525133</td>
<td class="formItem">PACK(68012-490, 68012-495)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>c249d29e-ed1d-4e8e-999e-409cc541576c</div>
<div>Set id: 35e89d4e-45cf-4374-bf93-fca8d40d783b</div>
<div>Version: 8</div>
<div>Effective Time: 20131021</div>
</div>
</div> <div class="DistributorName">Santarus, Inc.</div></p>
</body></html>
